President Trump wants to lower GLP-1 prices; Novo Nordisk hires new corporate affairs lead; FDA announces priority drug review candidates.

Novo Nordisk has named U.S. pharmaceutical executive Greg Miley as its new Global Head of Corporate Affairs, a strategic move as the Danish drugmaker faces heightened scrutiny from U.S. President Donald Trump over

After Omeros decided to hit pause on developing its MASP-3 inhibitor zaltenibart, Novo Nordisk has spied an opportunity to scoop up the rare disease drug.

Shares of Danish pharmaceutical giant Novo Nordisk are trading lower Friday morning, continuing an after-hours slide that began Thursday.

The FDA has declared a Novo Nordisk plant, key to drug manufacturing for some biotechs, out of compliance, which could delay approval of drugs made at the Indiana facility.

Get the latest healthcare stock updates, key pharma deals, and major legal developments impacting the S&P 500.

Novo had around 250 employees working on cell therapies, all of whom will be laid off, though a spokesperson declined to reveal which offices and locations will be affected.

The president said the cost of the drug should be much lower for Americans once negotiations with Novo Nordisk had concluded.